DDInter150 DDInter232
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy have few treatment options.[A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells. These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. Similar to [axicabtagene ciloleucel], brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3ζ-derived co-stimulatory domains.[A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR T cell preparation. Brexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under the tradename TECARTUS.
Azathioprine {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) downregulates {v} (Gene) RRP1B
RRP1B {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Budesonide
Budesonide {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Budesonide
Budesonide {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexucabtagene autoleucel
Azathioprine {u} (Compound) treats {v} (Disease) ulcerative colitis
ulcerative colitis {u} (Disease) is treated by {v} (Compound) Budesonide
Budesonide {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Azathioprine (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Azathioprine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Azathioprine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Azathioprine (Compound) downregulates RRP1B (Gene) and RRP1B (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Azathioprine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Azathioprine (Compound) treats ulcerative colitis (Disease) and ulcerative colitis (Disease) is treated by Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel